Literature DB >> 8014856

Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia.

S R Chaplan1, J W Pogrel, T L Yaksh.   

Abstract

Peripheral nerve lesions can result in exaggerated pain responses to low intensity mechanical stimuli (tactile allodynia). In the present work, the pharmacology of voltage-dependent calcium channels (VDCCs) involved in the transmission of neuropathic pain was characterized by examining the effects of antagonists specific to the N-, L- and P-type VDCCs, as well as an antagonist at a non-L-, non-N-type site. Drugs were administered via chronic lumbar intrathecal, i.v. or regional nerve block catheters implanted in rats with tactile allodynia induced by tight ligation of the left fifth and sixth lumbar spinal nerves. Intrathecally delivered N-type VDCC (omega-conopeptides SNX239, SNX159 and SNX111) produced dose-dependent blockade of tactile allodynia. Intrathecal L-type (diltiazem, verapamil and nimodipine), non-N-, non-L-type (omega-conopeptide SNX230) and P-type (omega-agatoxin IVA) VDCC antagonists had no effect on pain behavior at the highest doses examined. No VDCC antagonist suppressed paw withdrawal when administered i.v. SNX239, although effective when administered intrathecally, was without effect when applied regionally to the injured portion of the nerve. These results emphasize the importance of N-type, but not L- or P- type, VDCCs in the spinal cord on systems mediating persistent tactile allodynia after nerve injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014856

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  80 in total

1.  Developmental changes in calcium channel types mediating central synaptic transmission.

Authors:  S Iwasaki; A Momiyama; O D Uchitel; T Takahashi
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 2.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

3.  Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel.

Authors:  H Saegusa; T Kurihara; S Zong; A Kazuno ; Y Matsuda; T Nonaka; W Han; H Toriyama; T Tanabe
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

4.  Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.

Authors:  Molly S Crowe; Emma Leishman; Matthew L Banks; Ramesh Gujjar; Anu Mahadevan; Heather B Bradshaw; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

5.  Subtype-specific reduction of voltage-gated calcium current in medium-sized dorsal root ganglion neurons after painful peripheral nerve injury.

Authors:  J B McCallum; H-E Wu; Q Tang; W-M Kwok; Q H Hogan
Journal:  Neuroscience       Date:  2011-01-28       Impact factor: 3.590

Review 6.  Spinal agents for acute pain management.

Authors:  George Bowen; Eugene R Viscusi; Angelo Andonakakis
Journal:  Curr Pain Headache Rep       Date:  2004-02

Review 7.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 8.  Calcium channel functions in pain processing.

Authors:  John Park; Z David Luo
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

9.  Differential effects of voltage-gated calcium channel blockers on calcium channel alpha-2-delta-1 subunit protein-mediated nociception.

Authors:  E Chang; X Chen; M Kim; N Gong; S Bhatia; Z D Luo
Journal:  Eur J Pain       Date:  2014-08-27       Impact factor: 3.931

10.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.